{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-110654","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2025-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.098486+00:00","generated_at":"2026-05-17T10:48:08.072923+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Atossa Therapeutics receives Nasdaq extension to Feb 17, 2026 for bid price compliance","bullets":["Nasdaq notified Atossa on Feb 21, 2025 of non-compliance with $1.00 min bid price rule.","Initial compliance period ended Aug 20, 2025; extension granted to Feb 17, 2026.","Company may consider a reverse stock split to regain compliance.","No immediate impact on Nasdaq listing or trading of ATOS shares.","Atossa is monitoring bid price and evaluating available options."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-110654","json":"https://secwatch.observer/filing/0000950170-25-110654.json","markdown":"https://secwatch.observer/filing/0000950170-25-110654.md","text":"https://secwatch.observer/filing/0000950170-25-110654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000095017025110654/0000950170-25-110654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000095017025110654/atos-20250821.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:48:08.072923+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9daf815bcccb4101e4c728c36b527096b56961b8","claim":"ATOSSA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"February 21, 2025, Atossa Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company’s initial compliance period ended on August 20, 2025, and the Company subsequently requested an extension. On August 21, 2025, the Company was inf","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000095017025110654/0000950170-25-110654-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}